US Representative

Vince Fong Authored & Sponsored Legislation

Session

Primary Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB3810

Introduced
6/6/25  
SKIM Act Stopping Klepto-card and Identity Misuse Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB390

Introduced
1/14/25  
ACERO Act Advanced Capabilities for Emergency Response Operations Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB477

Introduced
1/16/25  
Making Advancements in Commercial Hypersonics Act or the MACH ActThis bill permits the National Aeronautics and Space Administration (NASA) to establish a research program to facilitate the testing of high-speed aircraft and related technologies, to be known as the Making Advancements in Commercial Hypersonics Program.Within a specified time period, NASA must develop a strategic plan for such research. NASA must also consult with the Department of Defense and the Federal Aviation Administration on these efforts. Under the program, NASA may not (1) fund the development of hypersonic and related technologies; or (2) enter into an agreement with certain foreign entities of concern, including entities owned or controlled by China, Iran, North Korea, or Russia. 

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB452

Introduced
1/15/25  
Refer
1/15/25  
Miracle on Ice Congressional Gold Medal Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB471

Introduced
1/16/25  
Refer
1/16/25  
Fix Our Forests Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB521

Introduced
1/16/25  
Ending Presidential Overreach on Public Lands Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB685

Introduced
1/23/25  
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB689

Introduced
1/23/25  
Refer
1/23/25  
FREE Act Full Responsibility and Expedited Enforcement Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB7

Introduced
1/22/25  
No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB703

Introduced
1/23/25  
Main Street Tax Certainty Act